Switch theme
Sign up to access all valuation multiples
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.
1926
981
LTM Revenue $960M
LTM EBITDA $139M
$638M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Guerbet has a last 12-month revenue (LTM) of $960M and a last 12-month EBITDA of $139M.
In the most recent fiscal year, Guerbet achieved revenue of $894M and an EBITDA of $115M.
Guerbet expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Guerbet valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $960M | XXX | $894M | XXX | XXX | XXX |
| Gross Profit | $960M | XXX | $661M | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | 74% | XXX | XXX | XXX |
| EBITDA | $139M | XXX | $115M | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| EBIT | $62.2M | XXX | $44.0M | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 5% | XXX | XXX | XXX |
| Net Profit | $21.1M | XXX | $26.8M | XXX | XXX | XXX |
| Net Margin | 2% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $352M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Guerbet's stock price is EUR 21 (or $23).
Guerbet has current market cap of EUR 260M (or $292M), and EV of EUR 568M (or $638M).
See Guerbet trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $638M | $292M | XXX | XXX | XXX | XXX | $1.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Guerbet has market cap of $292M and EV of $638M.
Guerbet's trades at 0.7x EV/Revenue multiple, and 5.5x EV/EBITDA.
Equity research analysts estimate Guerbet's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Guerbet has a P/E ratio of 13.8x.
See valuation multiples for Guerbet and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $292M | XXX | $292M | XXX | XXX | XXX |
| EV (current) | $638M | XXX | $638M | XXX | XXX | XXX |
| EV/Revenue | 0.7x | XXX | 0.7x | XXX | XXX | XXX |
| EV/EBITDA | 4.6x | XXX | 5.5x | XXX | XXX | XXX |
| EV/EBIT | 10.3x | XXX | 14.5x | XXX | XXX | XXX |
| EV/Gross Profit | 0.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | 13.8x | XXX | 10.9x | XXX | XXX | XXX |
| EV/FCF | 48.0x | XXX | -21.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialGuerbet's last 12 month revenue growth is 4%
Guerbet's revenue per employee in the last FY averaged $0.9M, while opex per employee averaged $0.6M for the same period.
Guerbet's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Guerbet's rule of X is 25% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Guerbet and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 4% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 15% | XXX | 13% | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 1% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 69% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Guerbet acquired XXX companies to date.
Last acquisition by Guerbet was XXXXXXXX, XXXXX XXXXX XXXXXX . Guerbet acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Guerbet founded? | Guerbet was founded in 1926. |
| Where is Guerbet headquartered? | Guerbet is headquartered in France. |
| How many employees does Guerbet have? | As of today, Guerbet has 981 employees. |
| Is Guerbet publicy listed? | Yes, Guerbet is a public company listed on PAR. |
| What is the stock symbol of Guerbet? | Guerbet trades under GBT ticker. |
| When did Guerbet go public? | Guerbet went public in 1989. |
| Who are competitors of Guerbet? | Similar companies to Guerbet include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Guerbet? | Guerbet's current market cap is $292M |
| What is the current revenue of Guerbet? | Guerbet's last 12 months revenue is $960M. |
| What is the current revenue growth of Guerbet? | Guerbet revenue growth (NTM/LTM) is 4%. |
| What is the current EV/Revenue multiple of Guerbet? | Current revenue multiple of Guerbet is 0.7x. |
| Is Guerbet profitable? | Yes, Guerbet is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Guerbet? | Guerbet's last 12 months EBITDA is $139M. |
| What is Guerbet's EBITDA margin? | Guerbet's last 12 months EBITDA margin is 15%. |
| What is the current EV/EBITDA multiple of Guerbet? | Current EBITDA multiple of Guerbet is 4.6x. |
| What is the current FCF of Guerbet? | Guerbet's last 12 months FCF is $13.3M. |
| What is Guerbet's FCF margin? | Guerbet's last 12 months FCF margin is 1%. |
| What is the current EV/FCF multiple of Guerbet? | Current FCF multiple of Guerbet is 48.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
